Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Gemcitabine in Relapsed or Refractory PTCL
NCT05105412Phase 2Terminated
- Sponsor
- National Health Research Institutes
- Start
- Jun 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide and gemcitabine in peripheral T-cell lymphoma (PTCL), sponsored by National Health Research Institutes. Started Jun 2022; status: terminated.
02
Drugs
lenalidomidegemcitabine
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05105412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105412.